CNS Drugs

, Volume 23, Issue 2, pp 139–156 | Cite as

Role of Antiepileptic Drugs in the Management of Eating Disorders

  • Susan L. McElroy
  • Anna I. Guerdjikova
  • Brian Martens
  • Paul E. KeckJr
  • Harrison G. Pope
  • James I. Hudson
Review Article

Abstract

Growing evidence suggests that antiepileptic drugs (AEDs) may be useful in managing some eating disorders. In the present paper, we provide a brief overview of eating disorders, the rationale for using AEDs in the treatment of these disorders and review the data supporting the effectiveness of specific AEDs in the treatment of patients with eating disorders. In addition, the potential mechanisms of action of AEDs in these conditions are discussed.

Of the available AEDs, topiramate appears to have the broadest spectrum of action as an anti-binge eating, anti-purging and weight loss agent, as demonstrated in two placebo-controlled studies in bulimia nervosa and three placebo-controlled studies in binge-eating disorder (BED) with obesity. Topiramate may also have beneficial effects in night-eating syndrome and sleep-related eating disorder, but controlled trials in these conditions are needed. The results of one small controlled study suggest that zonisamide may have efficacy in BED with obesity. However, both topiramate and zonisamide are associated with adverse effect profiles that may limit their use in patients with eating disorders. Phenytoin may be effective in some patients with compulsive binge eating, particularly if co-morbid EEG abnormalities are present, but available data are too varied to allow definitive conclusions to be made. Carbamazepine and valproate may be effective in treating patients with bulimia nervosa or anorexia nervosa when they are used to treat an associated psychiatric (e.g. mood) or neurological (e.g. seizure) disorder; otherwise, both agents, particularly valproate, are associated with weight gain.

In conclusion, AEDs have an emerging role in the management of some eating disorders.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Susan L. McElroy is a consultant to, or member of, the scientific advisory boards of Abbott Laboratories, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Ortho-McNeil and Wyeth-Ayerst, and is a principal or co-investigator on research studies sponsored by Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Esai, Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceuticals, Inc., National Institute of Mental Health (NIMH), Orexigen Therapeutics, Inc., Ortho-McNeil, Pfizer, Sanofi-Synthelabo, Somaxon Pharmaceuticals, Inc., Stanley Medical Research Institute and Takeda Pharmaceutical Company Ltd. She is also inventor on US Patent No. 6,323,236 B2 (McElroy SL: Use of sulfamate derivatives for treating impulse control disorders; filed 2000 Feb 18, approved 2001 Nov 27) and, along with the patent’s assignee (University of Cincinnati, Cincinnati, Ohio, USA), receives payments from Johnson & Johnson Pharmaceutical Research and Development, LLC, which has exclusive rights under the patent. Dr Paul E. Keck Jr is a principal or co-investigator on research studies sponsored by Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Company, Janssen Pharmaceutica, National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), Pfizer and UCB Pharma. He has also been reimbursed for consulting to Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Organon and Pfizer, and is an inventor on US Patent No. 6,387,956 (Shapira NA, Goldsmith TD, Keck Jr PE, University of Cincinnati: Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual; filed 1999 Mar 25, approved 2002 May 14). Dr Pope has participated in studies funded by Eli Lilly, Solvay and Ortho-McNeil Pharmaceuticals. Dr Hudson has consulted for Eli Lilly, Pfizer and Ortho-McNeil Pharmaceutical, and has received research grant support from Eli Lilly, Ortho-McNeil Pharmaceutical, Ortho-McNeil Janssen Scientific Affairs and Forest Laboratories. He has also provided expert testimony in litigation involving Forest Laboratories. Dr Guerdjikova and Mr Martens have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Hudson JI, Hiripi E, Pope Jr HG, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2006; 61: 348–58PubMedCrossRefGoogle Scholar
  2. 2.
    Yager J, Powers PS, editors. Clinical manual of eating disorders. Washington (DC): American Psychiatric Publishing, 2007Google Scholar
  3. 3.
    Winkelman JW. Sleep-related eating disorder and night eating syndrome: sleep disorders, eating disorders, or both? Sleep 2006; 29: 876–7PubMedGoogle Scholar
  4. 4.
    MacClancy J, Macbeth H, Henry J, et al. Consuming the inedible: cross-disciplinary approaches. Oxford: Berghahn, 2007Google Scholar
  5. 5.
    American Psychiatric Association. Treatment of patients with eating disorders. 3rd ed. Am J Psychiatry 2006; 163Suppl. 7: 4–54Google Scholar
  6. 6.
    Berkman ND, Bulik CM, Brownley KA, et al. Management of eating disorders. Evid Rep Technol Assess (Full Rep) 2006; 135: 1–166Google Scholar
  7. 7.
    Kaplan AS. Anticonvulsant treatment of eating disorders. In: Garfinkel PE, Garner DM, editors. The role of drug treatments for eating disorders. New York: Brunner/ Mazel, 1987: 96–123Google Scholar
  8. 8.
    Hudson JI, Pope Jr HG. The role of anticonvulsants in the treatment of bulimia. In: McElroy SL, Pope Jr HG, editors. Use of anticonvulsants in psychiatry. New York: Oxford University Press, 1988: 141–53Google Scholar
  9. 9.
    McElroy SL, Guerdjikova A, Keck Jr PE, et al. Anti-epileptic drugs in obesity, psychotropic-induced weight gain, and eating disorders. In: McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008; 283–309CrossRefGoogle Scholar
  10. 10.
    Bulik CM, Sullivan PF, Kendler KS. An empirical study of the classification of eating disorders. Am J Psychiatry 2000; 157: 886–95PubMedCrossRefGoogle Scholar
  11. 11.
    Wilfley DE, Bishop ME, Wilson GT, et al. Classification of eating disorders: toward DSM-V. Int J Eat Disord 2007; 40 Suppl.: S123–9PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization. International statistical classification of diseases. 10th ed. Geneva: World Health Organization, 2007Google Scholar
  13. 13.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  14. 14.
    Machado PP, Machado BC, Goncalves S, et al. The prevalence of eating disorders not otherwise specified. Int J Eat Disord 2007; 40: 212–7PubMedCrossRefGoogle Scholar
  15. 15.
    Rockert W, Kaplan AS, Olmsted MP. Eating disorder not otherwise specified: the view from a tertiary care treatment center. Int J Eat Disord 2007; 40 Suppl.: S99–103PubMedCrossRefGoogle Scholar
  16. 16.
    Papadioiykis V, Mimidis K. The rumination syndrome in adults: a review of the pathophysiology, diagnosis and treatment. J Postgrad Med 2007; 53: 203–6CrossRefGoogle Scholar
  17. 17.
    O’Reardon JP, Peshek A, Allison KC. Night eating syndrome: diagnosis, epidemiology and management. CNS Drugs 2005; 19: 997–1008PubMedCrossRefGoogle Scholar
  18. 18.
    Streigel-Moore RH, Franko DL, May A, et al. Should night eating syndrome be included in the DSM? Int J Eat Disord 2006; 39: 544–9CrossRefGoogle Scholar
  19. 19.
    American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual, 2nd ed. Westchester (IL): American Academy of Sleep Medicine, 2005Google Scholar
  20. 20.
    Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry 1998; 59: 14–9PubMedCrossRefGoogle Scholar
  21. 21.
    Plante DT, Winkelman JW. Parasomnias. Psychiatr Clin North Am. 2006; 29: 969–87PubMedCrossRefGoogle Scholar
  22. 22.
    Uher R, Treasure J. Brain lesions and eating disorders. J Neurol Neurosurg Psychiatry 2005; 76: 852–7PubMedCrossRefGoogle Scholar
  23. 23.
    Theisen FM, Linden A, König IR, et al. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003; 110: 111–21PubMedGoogle Scholar
  24. 24.
    Stunkard AJ. Eating patterns and obesity. Psychiatr Q 1959; 33: 284–95PubMedCrossRefGoogle Scholar
  25. 25.
    Volkow ND, O’Brien CP. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry 2007; 164: 708–10PubMedCrossRefGoogle Scholar
  26. 26.
    Devlin MJ. Is there a place for obesity in DSM-V? Int J Eat Disord 2007; 40 Suppl.: S83–8PubMedCrossRefGoogle Scholar
  27. 27.
    Gilmour J, Skuse D, Pembrey M. Hyperphagic short stature and Prader-Willi syndrome: a comparison of behavioral phenotypes, genotypes and indices of stress. Br J Psychiatry 2001; 179: 250–4CrossRefGoogle Scholar
  28. 28.
    Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005; 128: 2763–76PubMedCrossRefGoogle Scholar
  29. 29.
    Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuro-anatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005; 118: 45–50PubMedCrossRefGoogle Scholar
  30. 30.
    Rose EA, Porcerelli JH, Neale AV. Pica: common but commonly missed. J Am Board Fam Pract 2000; 13: 353–8PubMedGoogle Scholar
  31. 31.
    Rand CS, Macgregor AM, Stunkard AJ. The night eating syndrome in the general population and among postoperative obesity surgery patients. Int J Eat Disord 1997; 22: 65–9PubMedCrossRefGoogle Scholar
  32. 32.
    Winkelman JW, Herzog DB, Fava M. The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations. Psychol Med 1999; 29: 1461–6PubMedCrossRefGoogle Scholar
  33. 33.
    Hay P. Quality of life and bulimic eating disorder behaviors: findings from a community based sample. Int J Eat Disord 2003; 33: 434–42PubMedCrossRefGoogle Scholar
  34. 34.
    Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Comp Psychiatry 2007; 48: 124–31CrossRefGoogle Scholar
  35. 35.
    Hudson JI, Lalonde JK, Berry JM, et al. Binge eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry 2006; 63: 313–9PubMedCrossRefGoogle Scholar
  36. 36.
    Slof-Op’t Landt MC, van Furth EF, Meulenbelt I, et al. Eating disorders: from twin studies to candidate genes and beyond. Twin Res Hum Genet 2005; 8: 467–82Google Scholar
  37. 37.
    Javaris KN, Laird NM, Reichborn-Kjennerud T, et al. Familiality and heritability of binge eating disorder: results of a case-control family study and a twin study. Int J Eating Disord 2008; 41: 174–9CrossRefGoogle Scholar
  38. 38.
    Cnattingius S, Hultman CM, Dahl M, et al. Very preterm birth, birth trauma, and the risk of anorexia nervosa among girls. Arch Gen Psychiatry 1999; 56: 634–8PubMedCrossRefGoogle Scholar
  39. 39.
    Favaro A, Tenconi E, Santonastaso P. Perinatal factors and the risk of developing anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 2006; 63: 82–8PubMedCrossRefGoogle Scholar
  40. 40.
    National Institute for Clinical Excellence (NICE). Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline no 9. London: National Institute for Clinical Excellence, 2004 JanGoogle Scholar
  41. 41.
    Mond JM, Jay PJ, Rodgers B, et al. Health service utilization for eating disorders: findings from a community-based study. Int J Eat Disord 2007; 40: 399–408PubMedCrossRefGoogle Scholar
  42. 42.
    Hudson JI, Pope Jr HG, Carter WP. Pharmacologic therapy of bulimia nervosa. In: Goldstein E, editor. The management of eating disorders and obesity. Totowa (NJ): Humana Press, 1999: 19–32Google Scholar
  43. 43.
    Carter WP, Hudson JI, Lalonde JK, et al. Pharmacologic treatment of binge eating disorder. Int J Eat Disord 2003; 34 Suppl.: 74–88SCrossRefGoogle Scholar
  44. 44.
    Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 2004; 5: 301–7PubMedCrossRefGoogle Scholar
  45. 45.
    Steffen KJ, Roerig JL, Mitchell JE, et al. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs 2006; 11: 315–36PubMedCrossRefGoogle Scholar
  46. 46.
    Shapiro JR, Berkman ND, Brownley KA, et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 321–36PubMedCrossRefGoogle Scholar
  47. 47.
    Brownley KA, Berkman ND, Sedway JA, et al. Binge eating disorder treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 337–48PubMedCrossRefGoogle Scholar
  48. 48.
    McElroy SL, Guerdjikova AI, O’Melia A, et al. Pharmaco-therapy of the eating disorders. In: Agras WS, editor. Oxford handbook of eating disorders. New York: Oxford University Press. In pressGoogle Scholar
  49. 49.
    O’Reardon JP, Allison KC, Martino NS, et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry 2006; 163: 893–8PubMedCrossRefGoogle Scholar
  50. 50.
    Horne RL, Ferguson JM, Pope Jr HG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49: 262–6PubMedGoogle Scholar
  51. 51.
    Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial [published errata appear in JAMA 2006; 296: 934 and JAMA 2007; 298: 2008]. JAMA 2006; 295: 2605–12PubMedCrossRefGoogle Scholar
  52. 52.
    Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 310–20PubMedCrossRefGoogle Scholar
  53. 53.
    Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibu-tramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60: 1109–16PubMedCrossRefGoogle Scholar
  54. 54.
    Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenalin, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005; 22: 25–31PubMedCrossRefGoogle Scholar
  55. 55.
    Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008; 165: 51–8PubMedCrossRefGoogle Scholar
  56. 56.
    Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomized, double-blind trial. Lancet 2000; 355: 792–7PubMedCrossRefGoogle Scholar
  57. 57.
    McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390–8PubMedCrossRefGoogle Scholar
  58. 58.
    Provini F, Albani F, Vetrugno R, et al. A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder. Eur J Neurol 2005; 12: 432–6PubMedCrossRefGoogle Scholar
  59. 59.
    Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the treatment of low body weight and obsessional thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281–8PubMedCrossRefGoogle Scholar
  60. 60.
    Rogawski MA, Löscher W. The neurobiology of anti-epileptic drugs. Nat Rev Neurosci 2004; 5: 553–64PubMedCrossRefGoogle Scholar
  61. 61.
    Rogawski MA, Löscher W. The neurobiology of anti-epileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10: 685–92PubMedCrossRefGoogle Scholar
  62. 62.
    Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27–47PubMedCrossRefGoogle Scholar
  63. 63.
    White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85–110PubMedCrossRefGoogle Scholar
  64. 64.
    McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008Google Scholar
  65. 65.
    McElroy SL, Kotwal R, Keck Jr PE, et al. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005; 86: 107–27PubMedCrossRefGoogle Scholar
  66. 66.
    Brewerton TD, George MS. Is migraine related to the eating disorders? Int J Eat Disord 1993; 14: 75–9PubMedCrossRefGoogle Scholar
  67. 67.
    Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263–72PubMedCrossRefGoogle Scholar
  68. 68.
    Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677–85PubMedCrossRefGoogle Scholar
  69. 69.
    Johnson BA, Rosenthal N, Capece J, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641–51PubMedCrossRefGoogle Scholar
  70. 70.
    Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75: 233–40PubMedCrossRefGoogle Scholar
  71. 71.
    Polycarpon A, Papanikolaou P, Ioannidis JP, et al. Anti-convulsants for alcohol withdrawal. Cochrane Database Syst Rev 2005; (3): CD005064Google Scholar
  72. 72.
    Zanarini M. Antiepileptic drugs in personality disorders. In: McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008: 343–8CrossRefGoogle Scholar
  73. 73.
    Biton V. Effect of antiepileptic drugs on body weight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781–91PubMedCrossRefGoogle Scholar
  74. 74.
    Gao O, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett 2008; 582: 132–41PubMedCrossRefGoogle Scholar
  75. 75.
    Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92: 263–71PubMedCrossRefGoogle Scholar
  76. 76.
    Clifton PG, Kennett GA. Monoamine receptors in the regulation of feeding behaviour and energy balance. CNS Neurol Disord Drug Targets 2006; 5: 293–312PubMedCrossRefGoogle Scholar
  77. 77.
    Uevama E, Morikawa Y, Yasuda T, et al. Attenuation of fasting-induced phosphorylation of mitogen-activated protein kinases (ERK/p38) in the mouse hypothalamus in response to refeeding. Neurosci Lett 2004; 371: 40–4CrossRefGoogle Scholar
  78. 78.
    Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippo-campal extracellular glutamate monitored with a micro-dialysis electrode. Br J Pharmacol 1998; 124: 1277–85PubMedCrossRefGoogle Scholar
  79. 79.
    Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA trasporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003; 116: 1–6PubMedCrossRefGoogle Scholar
  80. 80.
    Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64: 2090–103PubMedCrossRefGoogle Scholar
  81. 81.
    Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007; 30: 230–40PubMedGoogle Scholar
  82. 82.
    Brill J, Lee M, Zhao S, et al. Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J Neurosci 2006; 26: 6813–22PubMedCrossRefGoogle Scholar
  83. 83.
    Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacol 2003; 28: 1292–9CrossRefGoogle Scholar
  84. 84.
    Kwak SE, Kim JE, Kim DS, et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuro-peptides 2005; 39: 507–13Google Scholar
  85. 85.
    McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial [published erratum appears in Am J Psychiatry 2003; 160: 612]. Am J Psychiatry 2003; 160: 255–61PubMedCrossRefGoogle Scholar
  86. 86.
    McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61: 1039–48PubMedCrossRefGoogle Scholar
  87. 87.
    McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1897–906PubMedCrossRefGoogle Scholar
  88. 88.
    Herridge PL, Pope Jr HG. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985; 5: 229–30PubMedCrossRefGoogle Scholar
  89. 89.
    McElroy SL, Keck Jr PE, Pope Jr HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16–24PubMedGoogle Scholar
  90. 90.
    Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273–94PubMedCrossRefGoogle Scholar
  91. 91.
    Greenway FL, Dahms WT, Bray GA. Phenytoin as a treatment of obesity associated with compulsive eating. Curr Ther Res 1977; 21: 338–42Google Scholar
  92. 92.
    Wermuth BM, Davis KL, Hollister LE, et al. Phenytoin treatment of binge eating syndrome. Am J Psychiatry 1977; 134: 1249–53PubMedGoogle Scholar
  93. 93.
    Green RS, Rau JH. Treatment of compulsive eating disturbances with anticonvulsant medication. Am J Psychiatry 1974; 131: 428–32PubMedGoogle Scholar
  94. 94.
    Rau JH, Green RS. Compulsive eating: a neuropsychologic approach to certain eating disorders. Compr Psychiatry 1975; 16: 223–31PubMedCrossRefGoogle Scholar
  95. 95.
    Weiss T, Levitz L. Diphenylhydantoin treatment of bulimia [letter]. Am J Psychiatry 1976; 133: 1093PubMedGoogle Scholar
  96. 96.
    Rau JH, Green RS. Soft neurological correlates of compulsive eaters. J Nerv Ment Dis 1978; 166: 435–7PubMedCrossRefGoogle Scholar
  97. 97.
    Moore SL, Rakes SM. Binge eating: therapeutic response to diphenylhydantoin [case report]. J Clin Psychiatry 1982; 43: 385–6PubMedGoogle Scholar
  98. 98.
    Parsons JM, Sapse AT. Significance of hypercortisolism in anorexia nervosa. J Orthomolecular Psychiatry 1985; 14: 13–8Google Scholar
  99. 99.
    Szyper MS, Mann JD. Anorexia nervosa as an interictal symptom of partial complex seizures [abstract]. Neurology 1978; 28: 335Google Scholar
  100. 100.
    Kaplan AS, Garfinkel PE, Darby PL, et al. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140: 1225–6PubMedGoogle Scholar
  101. 101.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980Google Scholar
  102. 102.
    Hudson JI, Pope Jr HG, Jonas JM, et al. Treatment of anorexia nervosa with antidepressants. J Clin Psychopharmacol 1985; 5: 17–23PubMedCrossRefGoogle Scholar
  103. 103.
    Young CR, Mazure CM. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. J Clin Psychiatry 1998; 59: 622PubMedCrossRefGoogle Scholar
  104. 104.
    Stewart JT. Treatment of coprophagia with carbamazepine [letter]. Am J Psychiatry 1995; 152: 295PubMedGoogle Scholar
  105. 105.
    Jawed SH, Krishnan VH, Prasher VP, et al. Worsening of pica as a symptom of depressive illness in a person with severe mental handicap. Br J Psychiatry 1993; 162: 835–7PubMedCrossRefGoogle Scholar
  106. 106.
    Tachibana N, Sugita Y, Teshima Y, et al. A case of anorexia nervosa associated with epileptic seizures showing favorable responses to sodium valproate and clonazepam. Jpn J Psychiatry Neurol 1989; 43: 77–84PubMedGoogle Scholar
  107. 107.
    Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368–72PubMedCrossRefGoogle Scholar
  108. 108.
    Schenck CH, Hurwitz TD, O’Connor KA, et al. Additional categories of sleep-related eating disorders and the current status of treatment. Sleep 1993; 16: 457–66PubMedGoogle Scholar
  109. 109.
    Yeh SB, Schenck CH. Sleep-related eating disorder in a 29 year-old man: a case report with diagnostic polysomno-graphic findings. Acta Neurol Taiwan 2007; 16: 106–10PubMedGoogle Scholar
  110. 110.
    McElroy SL, Keck Jr PE. Topiramate. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press. In pressGoogle Scholar
  111. 111.
    Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo controlled study. Biol Psychiatry 2005; 57: 495–9PubMedCrossRefGoogle Scholar
  112. 112.
    Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind placebo-controlled study. J Clin Psychiatry 2004; 65: 1515–9PubMedCrossRefGoogle Scholar
  113. 113.
    Nickel C, Lahman C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized double-blind, placebo-controlled study. J Affect Disord 2005; 87: 243–52PubMedCrossRefGoogle Scholar
  114. 114.
    Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335–41PubMedCrossRefGoogle Scholar
  115. 115.
    Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64: 1449–54PubMedCrossRefGoogle Scholar
  116. 116.
    Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005; 38: 295–300PubMedCrossRefGoogle Scholar
  117. 117.
    Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 1324–32PubMedCrossRefGoogle Scholar
  118. 118.
    Garner DM, Olmsted MP. Scoring the eating disorder inventory. Am J Psychiatry 1986; 143: 680–1PubMedGoogle Scholar
  119. 119.
    Garner DM, Garfinkel PE. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. Psychol Med 1979; 9: 273–9PubMedCrossRefGoogle Scholar
  120. 120.
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5PubMedCrossRefGoogle Scholar
  121. 121.
    Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare (ADM), 1976: 76–338Google Scholar
  122. 122.
    Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83Google Scholar
  123. 123.
    Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006–11Google Scholar
  124. 124.
    McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity [published erratum appears in J Clin Psychiatry 2005; 66: 138]. J Clin Psychiatry 2004; 65: 1463–9PubMedCrossRefGoogle Scholar
  125. 125.
    Barrat E, Stanford M. Impulsiveness: impulsiveness in personality characteristics of the personality disordered client. New York (NY): Wiley, 1995Google Scholar
  126. 126.
    Stunkard A, Messick S. Eating inventory manual. San Antonio (TX): The Psychological Corporation, Harcourt Brace & Company, 1988Google Scholar
  127. 127.
    Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11 Suppl 3: 89–95CrossRefGoogle Scholar
  128. 128.
    Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. Addict Behav 1982; 7: 47–55PubMedCrossRefGoogle Scholar
  129. 129.
    Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71PubMedCrossRefGoogle Scholar
  130. 130.
    Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry 2001; 158: 967–8PubMedGoogle Scholar
  131. 131.
    Appolinario JC, Fontenelle LF, Papelbaum M, et al. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002; 47: 271–3PubMedGoogle Scholar
  132. 132.
    Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge eating disorder. Bipolar Disord 2002; 4: 271–3PubMedCrossRefGoogle Scholar
  133. 133.
    Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorders. Am J Psychiatry 2002; 159: 1246–7PubMedCrossRefGoogle Scholar
  134. 134.
    Barbee JG. Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 2003; 33: 456–72CrossRefGoogle Scholar
  135. 135.
    De Bernardi C, Ferraris S, D’Innella P, et al. Topiramate for binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 339–41PubMedCrossRefGoogle Scholar
  136. 136.
    Zilberstein B, Pajecki D, Garcia de Brito AC, et al. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg 2004; 14: 802–5PubMedCrossRefGoogle Scholar
  137. 137.
    Guerdjikova AI, Kotwal R, McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg 2005; 15: 273–7PubMedCrossRefGoogle Scholar
  138. 138.
    Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001; 158: 322–3PubMedCrossRefGoogle Scholar
  139. 139.
    Dolberg OT, Barkai G, Gross Y, et al. Differential effects of topiramate in patients with traumatic brain injury and obesity: a case series. Psychopharmacol (Berl) 2005; 179: 838–45CrossRefGoogle Scholar
  140. 140.
    Winkelman JW. Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med 2003; 4: 243–6PubMedCrossRefGoogle Scholar
  141. 141.
    Tucker P, Masters B, Nawar O. Topiramate in the treatment of comorbid night eating syndrome and PTSD: a case study. Eat Disord 2004; 12: 75–8PubMedCrossRefGoogle Scholar
  142. 142.
    Winkelman JW. Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series. J Clin Psychiatry 2006; 67: 1729–34PubMedCrossRefGoogle Scholar
  143. 143.
    Martinez-Salio A, Soler-Algarra S, Calvo-Garcia I, et al. Nocturnal sleep-related eating disorder that responds to topiramate [in Spanish]. Rev Neurol 2007; 45: 276–9PubMedGoogle Scholar
  144. 144.
    Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1035–9PubMedCrossRefGoogle Scholar
  145. 145.
    Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. Am J Psychiatry 2002; 159: 2112–3PubMedCrossRefGoogle Scholar
  146. 146.
    Colom F, Vieta E, Benabarre H, et al. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62: 475–6PubMedCrossRefGoogle Scholar
  147. 147.
    Chung AM, Reed MD. Intentional topiramate ingestion in an adolescent female. Ann Pharmacother 2004; 38: 1439–42PubMedCrossRefGoogle Scholar
  148. 148.
    Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisa-mide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820–5PubMedCrossRefGoogle Scholar
  149. 149.
    McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004; 65: 50–6PubMedCrossRefGoogle Scholar
  150. 150.
    Cordas TA, Tavares H, Calderoni DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769–71PubMedCrossRefGoogle Scholar
  151. 151.
    Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: weight loss associated with levetiracetam. BMJ 2003; 327: 905PubMedCrossRefGoogle Scholar
  152. 152.
    Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. Epilepsia 2008; 49: 308–15PubMedCrossRefGoogle Scholar
  153. 153.
    Meredith CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine of obesity in adults. J Clin Psychiatry 2006; 67: 258–62CrossRefGoogle Scholar
  154. 154.
    Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287–91PubMedCrossRefGoogle Scholar
  155. 155.
    York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne-mendel rats fed a high-fat diet: alterations in hormones, neuro-peptide, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967–75PubMedCrossRefGoogle Scholar
  156. 156.
    Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000; 8: 656–63PubMedCrossRefGoogle Scholar
  157. 157.
    Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961–6PubMedCrossRefGoogle Scholar
  158. 158.
    Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002; 26: 344–53PubMedCrossRefGoogle Scholar
  159. 159.
    Lalonde J, Samson P, Poulin S, et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004; 80: 415–20PubMedCrossRefGoogle Scholar
  160. 160.
    Batterham RL, Ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007; 450: 106–9PubMedCrossRefGoogle Scholar
  161. 161.
    Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007; 15: 481–91PubMedCrossRefGoogle Scholar
  162. 162.
    Schiffer WK, Gerasimov MR, Marsteller DA, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 2001; 42: 196–8PubMedCrossRefGoogle Scholar
  163. 163.
    Nasser JA, Gluck ME, Geliebter A. Impulsivity and test meal intake in obese binge eating women. Appetite 2004; 43: 303–7PubMedCrossRefGoogle Scholar
  164. 164.
    McElroy S, Kotwal R. Binge eating. In: Hollander E, Stein DJ, editors. Clinical manual of impulse-control disorders. Washington, DC: American Psychiatric Publishing, 2006: 115–48Google Scholar
  165. 165.
    Wilkes JJ, Nguyen MT, Bandyopadhyay GK, et al. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp 30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 2005; 289: E1015–22PubMedCrossRefGoogle Scholar
  166. 166.
    Liang Y, Chen X, Osborne M, et al. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 2005; 7: 360–9PubMedCrossRefGoogle Scholar
  167. 167.
    Wilkes JJ, Nelson E, Osborne M, et al. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288: E617–24PubMedCrossRefGoogle Scholar
  168. 168.
    Ha E, Yim SV, Jung KH, et al. Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmaco-genomics J 2006; 6: 327–32Google Scholar
  169. 169.
    De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7: 879–84PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Susan L. McElroy
    • 1
    • 2
  • Anna I. Guerdjikova
    • 1
    • 2
  • Brian Martens
    • 1
    • 2
  • Paul E. KeckJr
    • 1
    • 2
  • Harrison G. Pope
    • 3
    • 4
  • James I. Hudson
    • 3
    • 4
  1. 1.Lindner Center of HOPEMasonUSA
  2. 2.Department of PsychiatryUniversity of Cincinnati College of MedicineCincinnatiUSA
  3. 3.Biological Psychiatry LaboratoryMcLean HospitalBelmontUSA
  4. 4.Department of PsychiatryHarvard Medical SchoolBostonUSA

Personalised recommendations